经导管动脉化疗栓塞分别联合微波消融与甲磺酸阿帕替尼治疗中晚期原发性肝癌的临床效果比较

Abstract
Figure/Table
References (16)
Related Citation (13)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with microwave ablation and Apatinib Mesylate in the treatment of intermediate and advanced primary liver cancer.Methods A total of 92 patients with primary liver cancer who were treated in the Department of Oncology of Jiujiang Third People′s Hospital from January 2018 to May 2019 were selected as subjects. They were divided into the microwave ablation group and the Apatinib Mesylate group according to random number table method, with 46 cases in each group. The microwave ablation group was given TACE combined with microwave ablation, and the Apatinib Mesylate group was given TACE combined with Apatinib Mesylate. The disease control rate (DCR), serum marker levels(serum alpha-fetoprotein [AFP], vascular endothelial growth factor [VEGF], matrix metalloproteinase-9 [MMP-9], cysteine aspartic proteinase-8 [caspase-8]), adverse events, and short-term survival rate were compared between the two groups. Results The DCR in the microwave ablation group was higher than that in the Apatinib Mesylate group, and the total incidence of adverse events in the microwave ablation group was lower than that in the Apatinib Mesylate group,with statistically significant differences (P<0.05). After treatment, the levels of serum AFP, VEGF and MMP-9 in the microwave ablation group were lower than those in the Apatinib Mesylate group, and the level of caspase-8 in the microwave ablation group was higher than that in the Apatinib Mesylate group, with statistically significant differences (P<0.05). There was no statistically significant difference in the one-year survival rate between the two groups (P>0.05).Conclusion TACE combined with Apatinib Mesylate or microwave ablation has a certain effect in the treatment of intermediate and advanced primary liver cancer. The two therapies have similar short-term survival rate, but TACE combined with microwave ablation has a better effect and the advantage of improving serum marker levels.

Key words： Intermediate and advanced primary liver cancer Transcatheter arterial chemoembolization Apatinib Mesylate Microwave ablation Disease control rate Serum markers

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Zefeng

Cite this article:

DENG Zefeng. Comparison of clinical effect of transcatheter arterial chemoembolization combined with microwave ablation and Apatinib Mesylate in treatment of intermediate and advanced primary liver cancer[J]. 中国当代医药, 2022, 29(8): 7-10.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I8/7

[1]	吴洁，董刚，刘婷婷，等.冷循环微波消融联合TACE 术治疗原发性肝癌的临床研究[J].肝脏，2020，25（10）：1058-1061.
[2]	张辉运，王小军，欧慧.经肝动脉灌注介入治疗对行肝癌微波消融术患者血清TK1 及CXCL13 水平的影响[J].中国医师杂志，2020，22（4）：559-563.
[4]	蔡争，宋建涛，饶航，等.甲磺酸阿帕替尼片联合肝动脉化疗栓塞治疗不可切除肝细胞肝癌患者的临床研究[J].中国临床药理学杂志，2020，36（23）：3903-3906.
[7]	陈韬，宁琴.终末期肝病合并感染诊治专家共识[J].中华传染病杂志，2018，36（8）：449-460.
[8]	张余飞，康静波，温居一，等.RECIST1.1 标准和mRECIST标准在原发性肝癌SBRT 治疗后疗效评价中的对比研究[J].中国肿瘤临床，2016，43（20）：902-906.
[3]	Elsheikh AM，Teama MI，Afify AF，et al.Trans -arterial chemoembolization （TACE） in treatment of non-resectable hepatocellular carcinoma：comparative study between conventional TACE and drug eluting bead TACE[J].IJRPS，2020，11（3）：4733-4741.
[5]	Shimose S，Iwamoto H，Tanaka M，et al.Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma[J].Oncology，2020，98（8）：558-565.
[6]	Sonsuz A.Barcelona Clinic Liver Cancer（BCLC）Staging：Does It Cover All Our Expectation[J].J Gastrointest Cancer，2017，48（3）：260-261.
[9]	双剑博，吴楠，严琦敏，等.超声引导结合腹腔镜对高危部位肝癌的微波消融治疗[J].中华普通外科杂志，2019，34（5）：449-450.
[10]	黄俊生，曾立，蔡俊义.艾迪注射液联合经肝动脉化疗栓塞术治疗中晚期肝癌效果观察[J].中国医药科学，2020，10（4）：251-253，276.
[11]	杨嘉文.TACE 分别联合微波消融、125I 放射性粒子植入及阿帕替尼靶向治疗大肝癌的疗效比较[J].中国医师杂志，2019，21（8）：1190-1194.
[12]	卞锦花，达婷，罗建梅，等.超声引导下经皮微波消融联合肝动脉化疗栓塞治疗原发性肝癌的疗效观察[J].中华实用诊断与治疗杂志，2020，34（5）：509-512.
[13]	Jingyan W，Linzhi Z，Xiaoming P，et al.Combination of TACE and FOLFOX4 in the treatment of unresectable advanced hepatocellular carcinoma：a prospective cohort study[J].OTM，2020，6（5）：208-216.
[14]	周传力，田世超，陈晓理，等.微波消融联合经肝动脉化疗栓塞术治疗原发性肝癌合并门静脉癌栓的效果及影响因素[J].临床肝胆病杂志，2019，35（10）：2220-2224.
[15]	徐新宝，殷杰，吉浩明，等.S-TACE 联合阿帕替尼对中晚期原发性肝癌患者肿瘤血管因子、肝功能和预后的影响[J].肝脏，2020，25（9）：933-936.
[16]	干霞，许涛，杜敏，等.B 超引导下肝癌微波消融治疗原发性肝癌的疗效及不良反应[J].实用癌症杂志，2020，35（2）：237-240.